ready for liftoff

Photos: The Cannon Houston's downtown space expects to open its doors early next month

The Cannon Houston's third location is planned to open on December 9. Photo courtesy of The Cannon

A Houston entrepreneurial hub plans to open its third coworking space location only a few weeks after its main campus debuted in West Houston.

The Cannon Houston's newest location will be a 17,000-square-foot space on the top floor of The Cannon Tower at Amegy on Main in Downtown Houston. The opening date for the new space is Monday, December 9.

The announcement follows the grand opening of The Cannon's 120,000-square-foot flagship space, which is now close to being completely leased by startups and small businesses, and represents another step in the company's ambitious expansion plan.

"We've long known that we will need multiple locations across Houston in order to serve our mission of supporting Houston's entrepreneurs, and we are thrilled to work with an incredibly forward-thinking organization like Amegy to continue to fulfill this mission," says Cannon founder and president, Lawson Gow, in a news release. "The Cannon Tower at Amegy on Main will be unlike any other space in the city, in which we will be developing a 'vertical village' of innovation, programs, and resources, transforming Amegy on Main into a hub for Downtown Houston's entrepreneurs."

Gow — who is the son of David Gow, owner of InnovationMap's parent company, Gow Media — recently transitioned into his position as The Cannon named Jon Lambert as CEO earlier this month.

The Cannon's space is just one part of the equation that is the Downtown Launch Pad — a joint project between Central Houston, Downtown Redevelopment Authority, The Cannon, and Amegy Bank. The Amegy building will also house MassChallenge and gener8or, as well as event and common space for programming on the 11th floor.

"Amegy Bank is thrilled to be a part of the expansion of the innovation community by offering space, amenities, and business development support," says Kelly Foreman, Amegy Bank's senior vice president and manager of corporate real estate and facilities, in a news release. "We have a long track record of helping businesses grow, and creating this space for a hub of start-ups and accelerators is yet another way to do just that."

Moving forward, The Cannon will play a role in expanding workspace, resources, and programming in the building. The space is now open for leasing, and the first 100 members to join the new space will receive free parking for the course of their membership.

Plans for growth

Photo courtesy of The Cannon

The Cannon Houston will be a major player as the Downtown Launch Pad expands throughout the building.

Trending News

Building Houston

 
 

Allterum Therapeutics Inc., a portfolio company of Fannin Innovation Studio, is using the funds to prepare for clinical trials. Photo via Getty Images

Allterum Therapeutics Inc. has built a healthy launchpad for clinical trials of an immunotherapy being developed to fight a rare form of pediatric cancer.

The Houston startup recently collected $1.8 million in seed funding through an investor group associated with Houston-based Fannin Innovation Studio, which focuses on commercializing biotech and medtech discoveries. Allterum has also brought aboard pediatric oncologist Dr. Philip Breitfeld as its chief medical officer. And the startup, a Fannin spinout, has received a $2.9 million grant from the Cancer Prevention Research Institute of Texas.

The funding and Breitfeld's expertise will help Allterum prepare for clinical trials of 4A10, a monoclonal antibody therapy for treatment of cancers that "express" the interleukin-7 receptor (IL7R) gene. These cancers include pediatric acute lymphoblastic leukemia (ALL) and some solid-tumor diseases. The U.S. Food and Drug Administration (FDA) has granted "orphan drug" and "rare pediatric disease" designations to Allterum's monoclonal antibody therapy.

If the phrase "monoclonal antibody therapy" sounds familiar, that's because the FDA has authorized emergency use of this therapy for treatment of COVID-19. In early January, the National Institute of Allergy and Infectious Diseases announced the start of a large-scale clinical trial to evaluate monoclonal antibody therapy for treatment of mild and moderate cases of COVID-19.

Fannin Innovation Studio holds exclusive licensing for Allterum's antibody therapy, developed at the National Cancer Institute. Aside from the cancer institute, Allterum's partners in advancing this technology include the Therapeutic Alliance for Children's Leukemia, Baylor College of Medicine, Texas Children's Hospital, Children's Oncology Group, and Leukemia & Lymphoma Society.

Although many pediatric patients with ALL respond well to standard chemotherapy, some patients continue to grapple with the disease. In particular, patients whose T-cell ALL has returned don't have effective standard therapies available to them. Similarly, patients with one type of B-cell ALL may not benefit from current therapies. Allterum's antibody therapy is designed to effectively treat those patients.

Later this year, Allterum plans to seek FDA approval to proceed with concurrent first- and second-phase clinical trials for its immunotherapy, says Dr. Atul Varadhachary, managing partner of Fannin Innovation Studio, and president and CEO of Allterum. The cash Allterum has on hand now will go toward pretrial work. That will include the manufacturing of the antibody therapy by Japan's Fujifilm Diosynth Biotechnologies, which operates a facility in College Station.

"The process of making a monoclonal antibody ready to give to patients is actually quite expensive," says Varadhachary, adding that Allterum will need to raise more money to carry out the clinical trials.

The global market for monoclonal antibody therapies is projected to exceed $350 billion by 2027, Fortune Business Insight says. The continued growth of these products "is expected to be a major driver of overall biopharmaceutical product sales," according to a review published last year in the Journal of Biomedical Science.

One benefit of these antibody therapies, delivered through IV-delivered infusions, is that they tend to cause fewer side effects than chemotherapy drugs, the American Cancer Society says.

"Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. They are designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells," the Mayo Clinic says.

Varadhachary says that unlike chemotherapy, monoclonal antibody therapy takes aim at specific targets. Therefore, monoclonal antibody therapy typically doesn't broadly harm healthy cells the way chemotherapy does.

Allterum's clinical trials initially will involve children with ALL, he says, but eventually will pivot to children and adults with other kinds of cancer. Varadhachary believes the initial trials may be the first cancer therapy trials to ever start with children.

"Our collaborators are excited about that because, more often than not, the cancer drugs for children are ones that were first developed for adults and then you extend them to children," he says. "We're quite pleased to be able to do something that's going to be important to children."

Trending News